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background: Atrial fibrillation (AF) is the most common arrhythmia in clinical practice and a major cause of morbidity and mortality. Fibrosis is an 
important feature of structural remodeling of the atria of patients with AF. The molecular mechanism underlying atrial fibrosis is not clearly identified, 
but atrial fibrosis appears to be an important mechanism leading to perpetuation of AF. The lysyl oxidase (LOX) family plays an important role in 
collagen crosslinking. The goal of this study was to characterize the expression of LOX, LOXL1 and LOXL2 in the atria of patients with persistent or 
permanent AF and correlate LOXL2 expression with left atria (LA) size and expression of other fibrotic genes.
methods: Samples of right atrial (RA) appendages of patients in sinus rhythm (SR), with persistent or permanent AF were obtained from patients 
that underwent cardiac surgery at Georg-August-University Göttingen. Gene expression of LOX family and fibrotic genes was determined using real-
time RT-PCR.
results: LOXL2 gene expression was significantly increased in the RA of patients with permanent AF up to an average of 5.0±1.2 fold relative to 
patients in SR. In contrast, the expression level of LOXL2 was not upregulated in the RA of persistent AF. The expression of LOX and LOXL1 in RA 
was not significantly different in persistent or permanent AF compared to SR. The expression of LOXL2 significantly correlated with LA size (r =0.66, 
p<0.05) in all patients. Expression levels of certain other fibrotic genes were measured. There were strong correlations among LOXL2, collagen I and 
TGF-β2 (r >0.9, p<0.0001). There were also significant correlations between LOXL2 and TGF-β1, LOXL2 and collagen III, LOXL2 and fibronectin, and 
LOXL2 and CTGF (r =0.43, 0.66, 0.72 and 0.53 respectively; p<0.05).
conclusions: LOXL2 mRNA expression was significantly upregulated in the RA of patients with permanent AF and the expression of this gene 
significantly correlated with LA size and the expression levels of other fibrotic genes including collagen I and III, TGF-β1, TGF-β2, fibronectin and 
CTGF. These results suggest that LOXL2 may be an important contributor to atrial fibrosis, a crucial substrate for maintenance of AF.
